925069-34-7
925069-34-7 結(jié)構(gòu)式
基本信息
2-(3-(4-氯苯甲?；?硫脲基)-4-乙基-5-甲基噻吩-3-甲酰胺
2-[(4-chlorobenzoyl)carbamothioylamino]-4-ethyl-5-methylthiophene-3-carboxamide
2-({[(4-chlorobenzoyl)amino]carbonothioyl}amino)-4-ethyl-5-methyl-3-thiophenecarboxamide
3-Thiophenecarboxamide, 2-[[[(4-chlorobenzoyl)amino]thioxomethyl]amino]-4-ethyl-5-methyl-
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-103489 | PI-273 PI-273 | 925069-34-7 | 1mg | 480元 |
| 2026/06/05 | HY-103489 | PI-273 PI-273 | 925069-34-7 | 5mg | 1120元 |
| 2026/06/05 | HY-103489 | PI-273 PI-273 | 925069-34-7 | 10mM * 1mLin DMSO | 1232元 |
常見問題列表
|
PI4KIIα 0.47 μM (IC 50 ) |
PI-273 (2 μM; 48 hours) blocks the cell cycle at the G2-M phase.
PI-273 (2 μM; 48 hours) induces cell apoptosis in all three Ras wild-type breast cancer cells: MCF-7, T-47D, and SK-BR-3.
PI-273 (0.5-2 μM; for 3 days) can suppress the AKT signaling pathway in a dose- and time-dependent manner.
PI-273 of 1 μM and 2 μM inhibits the cell proliferation of both MCF-7 and T-47D cells in a time-dependent manner.
Cell Cycle Analysis
| Cell Line: | MCF-7, T-47D, SK-BR-3, MDA-MB-231, SUM229PE, Hs 578T cells |
| Concentration: | 2 μM |
| Incubation Time: | 48 hours |
| Result: | Blocked the cell cycle at the G2-M phase. |
Apoptosis Analysis
| Cell Line: | MCF-7, T-47D, and SK-BR-3 cells |
| Concentration: | 2 μM |
| Incubation Time: | 48 hours |
| Result: | Induced cell apoptosis in all three Ras wild-type breast cancer cells: MCF-7, T-47D, and SK-BR-3. |
Western Blot Analysis
| Cell Line: | MCF-7 cells |
| Concentration: | 0.5, 1, 2 μM |
| Incubation Time: | For 3 days |
| Result: | Suppressed the AKT signaling pathway in a dose- and time-dependent manner. |
PI-273 (intraperitoneal injection; 25 mg/kg/day; 15 days) profoundly suppresses the tumor volume and weight in the MCF-7 xenografts.
PI-273 (0.5 mg/kg (intravenously) or 1.5 mg/kg (intragastrically); 0.08-5 hours) has a half-life of 0.411 hours for intravenous administration and 1.321 hours for intragastrical administration, and the absolute bioavailability of PI-273 is 5.1%.
| Animal Model: | Eight-week-old male BALB/c nude mice with MCF-7 cell |
| Dosage: | 25 mg/kg |
| Administration: | Intraperitoneal injection; daily; 15 days |
| Result: | Suppressed the tumor volume and weight in the MCF-7 xenografts. |
| Animal Model: | Male Sprague-Dawley (SD) rats |
| Dosage: | 0.5 mg/kg (intravenously) or 1.5 mg/kg (intragastrically) (Pharmacokinetic Study) |
| Administration: | Intravenously or intragastrically; 0.08, 0.16, 0.33, 0.67, 1, 1.5, 2, 3 and 5 hours |
| Result: | Has a half-life of 0.411 hours for intravenous administration and 1.321 hours for intragastrical administration, and the absolute bioavailability of PI-273 is 5.1%. |